Wall Street analysts’ estimates
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.
The above chart shows analysts’ recommendations for Ionis’s stock over the last 12 months.
Ionis’s stock price has decreased by nearly 15.9% over the last 12 months and decreased by 12.1% in 2018 year-to-date. Analysts’ estimates show that the stock has a potential to return ~29.9% over the next 12 months. Wall Street analysts’ recommendations show a 12-month targeted price of $57.42 per share as compared to the last price of $44.20 per share as of August 7.
Of the 14 analysts tracking Ionis Pharmaceuticals on August 8, one recommends a “strong buy,” three recommend a “buy,” seven recommend a “hold,” two recommend a “sell,” and one recommends a “strong sell.” The consensus rating for Ionis Pharmaceuticals stands at 2.93, which represents a moderate buy for value investors.
The Invesco Dynamic Biotechnology & Genome ETF (PBE) holds 2.3% of its total investments in Ionis (IONS), 3.2% in Sarepta Therapeutics (SRPT), 4.8% in Amgen (AMGN), and 5.0% in Gilead Sciences (GILD).